loading page

How to reduce endogenous adrenaline synthesis in patients with a dysfunctional renal medulla using an APZ-BMZ-DXM combination therapy - preliminary report
  • +1
  • Dr. Carolina Diamandis,
  • Riku Honda,
  • Fabio Rocha,
  • Ali Shirazi
Dr. Carolina Diamandis

Corresponding Author:diamandis@lazar-consortium.com

Author Profile
Riku Honda
Fabio Rocha
Ali Shirazi


Adrenaline, also known as epinephrine, is a hormone and neurotransmitter produced by the adrenal gland. It is an essential component of the fight-or-flight response, a survival mechanism that prepares the body to respond to perceived danger. When the body experiences stress, the hypothalamus activates the adrenal gland's medulla, which releases adrenaline into the bloodstream. However, some people suffer from chronically elevated hyperadrenergic conditions, mostly secondary to another disease. These conditions can lead to a wide range of symptoms, including anxiety, panic attacks, heart disease, tremors, sweating, and difficulty sleeping. In severe cases, it can even lead to heart failure, stroke, and death. The reduction of endogenous adrenaline synthesis is an important part of managing hyperadrenergic situations. Endogenous adrenaline refers to the adrenaline produced by the body, as opposed to exogenous adrenaline, which is adrenaline that is taken as a medication. By reducing the amount of adrenaline produced by the body, it is possible to relieve the symptoms of hyperadrenergic conditions and improve the quality of life for those affected. This preliminary paper presents a new medication regimen which is, to our knowledge, the most effective one so far.